リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Development of an Assay Method for Evaluating Cell Fusion Events Using Split Luciferase Reconstitution Techniques」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Development of an Assay Method for Evaluating Cell Fusion Events Using Split Luciferase Reconstitution Techniques

李, 喬婧 東京大学 DOI:10.15083/0002001487

2021.09.08

概要

1. Introduction
Myogenesis-promoting chemicals are an important source of new pharmaceuticals for the treatment of skeletal muscle atrophy that impairs quality of life. Development of new drugs to treat such muscle wasting requires a robust and quantitative screening method that detects myogenesis. As myocyte fusion is a key step in myogenesis to generate functional skeletal muscles, a widely used approach to estimate myocytes fusion is the use of the fusion index, which is a ratio of the number of nuclei inside the myotubes to the total number of nuclei. However, because detection and counting of nuclei under a fluorescence microscopy are time consuming, this index is not suited for high-throughput screening for myogenesis-promoting compounds. This shortcoming can be overcome by simple fluorescence-based analysis, which correlates myogenesis extent with fluorescence intensity. However, the fluorescence approaches generally have difficulty in screening of chemical libraries: a number of library members possibly show fluorescence, generating high-background signals that disrupt precise estimation of myogenesis. Therefore, a new myogenesis-detection approach must be devised for high-throughput screening of myogenesis-promoting compounds without using microscopy or fluorescence detection.

Herein, we describe a novel bioluminescence-based assay system for evaluating myogenesis, aimed at high-throughput screening of chemical compound libraries to identify myogenesis-promoting chemicals. In this system, a pair of genetically encoded probes based on a protein trans-splicing and split luciferase reconstitution techniques was designed. C2C12 myoblast cells expressing either of the probes were prepared and cultured in the same cultivation dishes. Fusion of the cells that occurs in the myogenesis process results in encounter of the probes to each other in the cytoplasm. Then the cell fusion was detected from the luminescence of reconstituted Fluc generated through protein trans-splicing reactions. Using this assay system, we performed high-throughput screening for a chemical-compound library and identified two chemical compounds, Imatinib and Doxazosin mesylate, as myogenesis-promoting agents.

2. Results and discussion
2-1. The scheme of the probe for detecting the cell fusion
Firefly luciferase (Fluc) and an intein of DnaE derived from the cyanobacterium Synechocystis sp. strain PCC 6803 were used to design a pair of the probes. Fluc was split at the position between 415 and 416 amino acids, producing N-terminal and C-terminal fragments: FlucN and FlucC, respectively. The split DnaE inteins comprise N-terminal 123 amino acids (DnaEn) and C-terminal 36 amino acids (DnaEc). One probe is the FlucN fused with the DnaEn (N-probe), while the other probe is the DnaEc fused with FlucC (C-probe). (Fig. 2-1A) Then, two stable cell lines that express either N-probe or C-probe were established based on a C2C12 myoblast cell line (N-cell and C-cell, respectively). N-cell and C-cell were mixture to induce the differentiation and myogenesis. Thus, cell fusion between the N-cells and C-cells during the myogenesis allows the N-probes to encounter the C-probes in the cytoplasm, triggering a protein trans-splicing reaction by DnaEn and DnaEc to connect FlucN with FlucC via a peptide bond between the serine (S) and cysteine (C) and form reconstituted Fluc. (Fig. 2-1B)

2-2. Characterization of the N-cells and C-cells.
The N-cell and C-cell were developed by respectively introducing the N-probe (N-cell) and C-probe (C-cell) into the C2C12 cell. We evaluated them from the aspects of the ability in forming myotubes, the expression of corresponding probe and the production of luminescence before and after cell differentiation.

The results of evaluation were as follows. The N-cells and C-cells were undifferentiated initially but differentiated and fused into myotubes after the induction of differentiation. The N-probes were expressed stably in the N-cells and the N-C cell mixture. And the reconstituted Fluc was also observed in the mixed samples from Day 4. However, the C-probes were degraded by proteasome degradation pathway when the probe existed alone in the C2C12 cells (C-cells), whereas the C-probe was stabilized through the interaction with the N-probe when the N-cell fuses to the C-cell. A luminescence signal was not detectable from the N-cells and C-cells neither before or after differentiation, or from the mixture of N-cells and C-cells before differentiation. But, an obvious luminescence signal was obtained from the N-C cell mixture after differentiation.

2-3. Correlation of luminescence intensity with differentiation and cell fusion.
To evaluate myogenesis extent, the luminescence signal generated from the mixture of N-cells and C-cells should correlated with the frequency of cell fusion. Therefore, the correlation between the luminescence intensity and the cell fusion frequency was investigated. When the luminescence intensity was show against the fusion index according to the differentiation days, the luminescence intensity showed a linear correlation with fusion index (Fig. 2-9C). The results indicated the use of N-cell and C-cell as an indicator of cell fusion in myogenesis with comparable performance of the fusion index.

2-4. The 96-well plate-based assay using the N-cell and C-cell for evaluating myogenesis-promotion by chemical compounds
To assess the applicability of the present system in estimation of the drug efficacy for myogenesis induction in a 96-well plate scale, the progression of cell fusion upon treatment with myogenesis promoters, β-guanidinopropionic acid (GPA, 1.0 mmol L-1 ) and Insulin-like growth factor 1 (IGF-1, 10 ng mL-1 ) and an inhibitor, tumor necrosis factor alpha (TNFα, 20 ng mL-1 ) were assessed.

The imaging data (Fig. 2-10A) show the promotion of myotube formation by GPA and IGF-1 while the inhibition by TNFα as expected. And then, the mixture of N-cells and C-cells were cultivated on a 96-well plate to induce the differentiation in the presence of each chemicals, respectively, and the luminescence intensity was counted well by well for 1 s per well. As a result, the decrease/increase in luminescence intensities for the TNFα, the IGF-1, and the GPA groups were consistent with the effects of these agents (Fig. 2-10B).

2-5. Evaluation of the 96-well plate-based assay for a high-throughput screening of myogenesis-promoting chemical compounds
To validate the robustness and quality of the system in the 96-well plate-based assay, Z’-factor was determined. In the determination, DMSO (0.1%) and IGF-1(10 ng mL-1 ) were used as negative and positive controls, respectively. As a result, a Z’-factor of 0.44±0.05 (Mean±SD) were determined for the 96-well plate-base assay. As the value was in the range of acceptance criterion (Z’- factor ≥ 0.4), the present system showed a sufficient robustness for 96-well plate-based assay to identify chemical compounds that promote myogenesis with the same efficacy as IGF-1.

2-6. Discovery of Imatinib and Doxazosin mesylate for their promoting effects on myogenesis by screening library chemical compounds by using the present 96-well plate assay.
The 96-well microtiter plate-based assay was applied to a high-throughput screening of myogenesis-promoting compounds in 1,191 pharmacologically proven bioactive small molecules (Prestwick Chemical). As a result, two hits compounds, Imatinib and Doxazosin mesylate, were obtained. (Fig. 3-2) In addition, dose-dependent effects of Imatinib and Doxazosin mesylate on myogenesis of C2C12 cells were investigated by the present assay as well as the conventional evaluation of fusion index. Two results were consistent that the optimum concentration for promoting the myogenesis of C2C12 cells was ascertained to be 6.0 μmol L-1 for Imatinib and 4.0 μmol L-1 for Doxazosin mesylate, respectively.

3. Conclusion
In this study, a robust assay that enables the detection of cell fusion in myogenesis process was developed using protein trans-splicing based luciferase reconstitution technique. The assay method allows quantitative assessment of myogenesis through the luminescence intensity. Because the system is sufficiently sensitive for determining myogenesis promotion of C2C12 cells in a 96-well microtiter plate scale, it is applicable for screening myogenesis-promoting compounds in a high-throughput manner. As a proof of consisting of 1,191 drugs, we found imatinib and doxazosin mesylate to possess a myogenesis-promoting activity in C2C12 cells. Our method may be useful for basic myogenesis studies, tissue engineering and drug discovery. The pair of luciferase probes can be used in broad applications to assess cell fusion events including those accompanied with fusion of nuclei.

この論文で使われている画像

参考文献

(1) Janssen, I., Heymsfield, S. B., Wang, Z. M., and Ross, R. (2000) Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J. Appl. Physiol. 89, 81–88.

(2) Ostrovidov, S., Hosseini, V., Ahadian, S., Fujie, T., Parthiban, S. P., Ramalingam, M., Bae, H., Kaji, H., and Khademhosseini, A. (2014) Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications. Tissue Eng. 20, 403–436.

(3) Le Grand, F., and Rudnicki, M. A. (2007) Skeletal muscle satellite cells and adult myogenesis. Curr. Opin. Struct. Biol. 19, 628–633.

(4) Evans, W. J. (2010) Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am. J. Clin. Nutr. 91, 1123S–1127S.

(5) Dumont, N. A., Wang, Y. X., and Rudnicki, M. A. (2015) Intrinsic and extrinsic mechanisms regulating satellite cell function. Development 142, 1572–1581.

(6) Andrs, V., and Walsh, K. (1996) Myogenin expression , cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J. Cell Biol. 132, 657–666.

(7) Nguyen, N.-U.-N., and Wang, H.-V. (2015) Dual roles of palladin protein in in vitro myogenesis: inhibition of early induction but promotion of myotube maturation. PLoS One 10, e0124762.

(8) Pomi Es, P., Rodriguez, J., Blaqui Ere, M., Sedraoui, S., Gouzi, F., Carnac, G., Laoudj-Chenivesse, D., Mercier, J., Pr Efaut, C., and Hayot, M. (2015) Reduced myotube diameter, atrophic signalling and elevated oxidative stress in cultured satellite cells from COPD patients. J. Cell Mol. Med. 19, 175–186.

(9) Agley, C. C., Velloso, C. P., Lazarus, N. R., and Harridge, S. D. R. (2012) An image analysis method for the precise selection and quantitation of fluorescently labeled cellular constituents: application to the measurement of human muscle cells in culture. J. Histochem. Cytochem. 60, 428–438.

(10) Bajaj, P., Reddy, B., Millet, L., Wei, C., Zorlutuna, P., Bao, G., and Bashir, R. (2011) Patterning the differentiation of C2C12 skeletal myoblasts. Integr. Biol. 3, 897–909.

(11) Pajcini, K. V, Pomerantz, J. H., Alkan, O., Doyonnas, R., and Blau, H. M. (2008) Myoblasts and macrophages share molecular components that contribute to cell– cell fusion 180, 1005–1019.

(12) Veliça, P., and Bunce, C. M. (2011) A quick, simple and unbiased method to quantify C2C12 myogenic differentiation. Muscle and Nerve 44, 366–370.

(13) Miyake, T., McDermott, J. C., and Gramolini, A. O. (2011) A method for the direct identification of differentiating muscle cells by a fluorescent mitochondrial dye. PLoS One 6, e28628.

(14) Kodaka, M., Yang, Z., Nakagawa, K., Maruyama, J., and Xu, X. (2015) A new cell-based assay to evaluate myogenesis in mouse myoblast C2C12 cells. Exp. Cell Res. 336, 171–181.

(15) Kodaka, M., Xu, X., Yang, Z., Maruyama, J., and Hata, Y. (2017) Application of Split-GFP Reassembly Assay to Study Myogenesis and Myofusion In Vitro. Methods Mol Bio. 1668, 127–134.

(16) Thorne, N., Inglese, J., and Auld, D. S. (2010) Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem. Biol. 17, 646–657.

(17) Yu, W., and Hardin, P. E. (2007) Use of firefly luciferase activity assays to monitor circadian molecular rhythms in vivo and in vitro. Methods Mol Bio. 362, 465–480.

(18) Li, J.-F., Bush, J., Xiong, Y., Li, L., and McCormack, M. (2011) Large-scale protein-protein interaction analysis in arabidopsis mesophyll protoplasts by split firefly luciferase complementation. PLoS One (Somers, D. E., Ed.) 6, e27364.

(19) Tiffen, J. C., Bailey, C. G., Ng, C., Rasko, J. E., and Holst, J. (2010) Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol. Cancer 9, 299–306.

(20) Ando, Y., Niwa, K., Yamada, N., Enomoto, T., Irie, T., Kubota, H., Ohmiya, Y., and Akiyama, H. (2008) Firefly bioluminescence quantum yield and colour change by pH-sensitive green emission. Nat. Photonics 2, 44–47.

(21) Kim, J., and Somers, D. E. (2010) Rapid assessment of gene function in the circadian clock using artificial microRNA in arabidopsis mesophyll protoplasts. Plant Physiol. 154, 611–621.

(22) Pichler, A., Prior, J. L., and Piwnica-Worms, D. (2004) Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc. Nati. Acad. Sci. 101, 1702–1707.

(23) Fan, F., and Wood, K. (2007) Bioluminescent assays for high-throughput screening. Assay Drug Dev. Technol. 5, 127–136.

(24) Razgulin, A., Ma, N., and Rao, J. (2011) Strategies for in vivo imaging of enzyme activity: an overview and recent advances. Chem. Soc. Rev. 40, 4186–4216.

(25) Fukutani, Y., Ishii, J., Kondo, A., Ozawa, T., Matsunami, H., and Yohda, M. (2017) Split luciferase complementation assay for the analysis of G proteincoupled receptor ligand response in Saccharomyces cerevisiae. Biotechnol. Bioeng. 114, 1354–1361.

(26) Takenouchi, O., Kanno, A., Takakura, H., Hattori, M., and Ozawa, T. (2016) Bioluminescent Indicator for Highly Sensitive Analysis of Estrogenic Activity in a Cell-Based Format. Bioconjug. Chem. 27, 2689–2694.

(27) Luker, K. E., Smith, M. C. P., Luker, G. D., Gammon, S. T., Piwnica-Worms, H., and Piwnica-Worms, D. (2004) Kinetics of regulated protein–protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc. Nati. Acad. Sci. 101, 12288–12293.

(28) Kim, S. B., Awais, M., Sato, M., Umezawa, Y., and Tao, H. (2007) Integrated molecule-format bioluminescent probe for visualizing androgenicity of ligands based on the intramolecular association of androgen receptor with its recognition peptide. Anal. Chem. 79, 1874–1880.

(29) Kim, S. B., Kanno, A., Ozawa, T., Tao, H., and Umezawa, Y. (2007) Nongenomic activity of ligands in the association of androgen receptor with Src. ACS Chem. Biol. 2, 484–492.

(30) Paulmurugan, R., and Gambhir, S. S. (2005) Firefly luciferase enzyme fragment complementation for imaging in cells and living animals. Anal. Chem. 77, 1295– 1302.

(31) Ozawa, T., Kaihara, A., Sato, M., Tachihara, K., and Umezawa, Y. (2001) Split luciferase as an optical probe for detecting protein−protein interactions in mammalian cells based on protein splicing. Anal. Chem. 73, 2516–2521.

(32) Gehl, C., Kaufholdt, D., Hamisch, D., Bikker, R., Kudla, J., Mendel, R. R., and Hänsch, R. (2011) Quantitative analysis of dynamic protein-protein interactions in planta by a floated-leaf luciferase complementation imaging (FLuCI) assay using binary Gateway vectors. Plant J. 67, 542–553.

(33) Fujikawa, Y., and Kato, N. (2007) Split luciferase complementation assay to study protein-protein interactions in Arabidopsis protoplasts. Plant J. 52, 185–195.

(34) Stains, C. I., Furman, J. L., Porter, J. R., Rajagopal, S., Li, Y., Wyatt, R. T., and Ghosh, I. (2010) A general approach for receptor and antibody-targeted detection of native proteins utilizing split-luciferase reassembly. ACS Chem. Biol. 5, 943– 952.

(35) Paulmurugan, R., Umezawa, Y., and Gambhir, S. S. (2002) Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies. Proc. Natl. Acad. Sci. U. S. A. 99, 15608–15613.

(36) Yoshimura, H., and Ozawa, T. (2014) Methods of Split Reporter Reconstitution for the Analysis of Biomolecules. Chem. Rec. 14, 492–501.

(37) Kane, P. M., Yamashiro, C. T., Wolczyk, D. F., Neff, N., Goebl, M., and Stevens, T. H. (1990) Protein splicing converts the yeast TFP1 gene product to the 69-kD subunit of the vacuolar H(+)-adenosine triphosphatase. Science 250, 651–657.

(38) Hirata, R., Ohsumk, Y., Nakano, A., Kawasaki, H., Suzuki, K., and Anraku, Y. (1990) Molecular structure of a gene, VMA1, encoding the catalytic subunit of H(+)-translocating adenosine triphosphatase from vacuolar membranes of Saccharomyces cerevisiae. J. Biol. Chem. 265, 6726–6733.

(39) Mills, K. V, Johnson, M. A., and Perler, F. B. (2014) Protein plicing: show inteins escape from precursor proteins. J. Biol. Chem. 289, 14498–14505.

(40) Yaffe, D., and Saxel, O. (1977) Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270, 725–727.

(41) McMahon, D. K., Anderson, P. A., Nassar, R., Bunting, J. B., Saba, Z., Oakeley, A. E., and Malouf, N. N. (1994) C2C12 cells: biophysical, biochemical, and immunocytochemical properties. Am. J. Physiol. 266, C1795-1802.

(42) Rajan, S., Dang, H. C. P., Djambazian, H., Zuzan, H., Fedyshyn, Y., Ketela, T., Moffat, J., Hudson, T. J., and Sladek, R. (2012) Analysis of early C2C12 myogenesis identifies stably and differentially expressed transcriptional regulators whose knock-down inhibits myoblast differentiation. Physiol. Genomics 44, 183– 197.

(43) Burattini, S., Ferri, P., Battistelli, M., Curci, R., Luchetti, F., and Falcieri, E. (2004) C2C12 murine myoblasts as a model of skeletal muscle development: morpho-functional characterization. Eur. J. Histochem. 48, 223–234.

(44) Cabane, C., Englaro, W., Yeow, K., Ragno, M., and Dérijard, B. (2003) Regulation of C2C12 myogenic terminal differentiation by MKK3/p38α pathway. Am. J. Physiol. Physiol. 284, C658-666.

(45) Yaffe, D., and Saxel, O. (1977) A myogenic cell line with altered serum requirements for differentiation. Differentiation. 7, 159–166.

(46) Luchetti, F., Gregorini, A., Papa, S., Burattini, S., Canonico, B., Valentini, M., and Falcieri, E. (1998) The K562 chronic myeloid leukemia cell line undergoes apoptosis in response to interferon-alpha. Haematologica 83, 974–980.

(47) Luchetti, F., Burattini, S., Ferri, P., Papa, S., and Falcieri, E. (2002) Actin involvement in apoptotic chromatin changes of hemopoietic cells undergoing hyperthermia. Apoptosis 7, 143–52.

(48) Zamai, L., Burattini, S., Luchetti, F., Canonico, B., Ferri, P., Melloni, E., Gonelli, A., Guidotti, L., Papa, S., and Falcieri, E. (2004) In vitro apoptotic cell death during erythroid differentiation. Apoptosis 9, 235–246.

(49) Burattini, S., Luchetti, F., Battistelli, M., Della Felice, M., Papa, S., Piersanti, G., Tarzia, G., and Falcieri, E. (2003) 5-(2-Ethyl-phenyl)-3-(3-methoxy-phenyl)-1H- [1,2,4]triazole (DL-111-IT) and related compounds induce apoptotic patterns in cultures of human tumor cell lines. J. Biol. Regul. Homeost. Agents 17, 348–357.

(50) Kanno, A., Yamanaka, Y., Hirano, H., Umezawa, Y., and Ozawa, T. (2007) Cyclic luciferase for real-time sensing of caspase-3 activities in living mammals. Angew. Chemie 119, 7739–7743.

(51) Wu, H., Hu, Z., and Liu, X.-Q. (1998) Protein trans-splicing by a split intein encoded in a split DnaE gene of Synechocystis sp. PCC6803. Proc. Natl. Acad. Sci. 95, 9226–9231.

(52) Volkmann, G., and Iwaï, H. (2010) Protein trans-splicing and its use in structural biology: opportunities and limitations. Mol. Biosyst. 6, 2110–2121.

(53) Cowan, J. L., and Morley, S. J. (2004) The proteasome inhibitor, MG132, promotes the reprogramming of translation in C2C12 myoblasts and facilitates the association of hsp25 with the eIF4F complex. Eur. J. Biochem. 271, 3596–3611.

(54) Sun, L., Trausch-Azar, J. S., Ciechanover, A., and Schwartz, A. L. (2005) Ubiquitin-proteasome-mediated degradation, intracellular localization, and protein synthesis of MyoD and Id1 during muscle differentiation. J. Biol. Chem. Chem. 280, 26448–26456.

(55) Sun, Y., Ge, Y., Drnevich, J., Zhao, Y., Band, M., and Chen, J. (2010) Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J. Cell Biol. 189, 1157–1169.

(56) Ohira, Y., Matsuoka, Y., Kawano, F., Higo, Y., Ohira, T., Terada, M., Oke, Y., Igo, Y. H., Hira, T. O., Erada, M. T., Ke, Y. O., and Akai, N. N. (2011) Effects of creatine and its analog , β-guanidinopropionic acid , on the differentiation of and nucleoli in myoblasts on the differentiation of and nucleoli in myoblasts. Biosci. Biotechnol. Biochem. 75, 1085–1089.

(57) Baumgarner, B. L., Nagle, A. M., Quinn, M. R., Farmer, A. E., and Kinsey, S. T. (2015) Dietary supplementation of β-guanidinopropionic acid (βGPA) reduces whole-body and skeletal muscle growth in young CD-1 mice. Mol. Cell. Biochem. 403, 277–285.

(58) Latres, E., Amini, A. R., Amini, A. A., Griffiths, J., Martin, F. J., Wei, Y., Hsin, C. L., Yancopoulos, G. D., and Glass, D. J. (2005) Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3- kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. 280, 2737–2744.

(59) Miyazaki, M., McCarthy, J. J., and Esser, K. A. (2010) IGF-1-induced phosphorylation and altered distribution of TSC1/ TSC2 in C2C12 myotubes. Febs J. 277, 2180–2191.

(60) Coletti, D., Yang, E., Marazzi, G., and Sassoon, D. (2002) TNFα inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J. 21, 631–642.

(61) Zhao, Q., Yang, S. T., Wang, J. J., Zhou, J., Xing, S. S., Shen, C. C., Wang, X. X., Yue, Y. X., Song, J., Chen, M., Wei, Y. Y., Zhou, Q. P., Dai, T., and Song, Y. H. (2015) TNF alpha inhibits myogenic differentiation of C2C12 cells through NF- κB activation and impairment of IGF-1 signaling pathway. Biochem. Biophys. Res. Commun. 458, 790–795.

(62) Yang, L., Nasu, Y., Hattori, M., Yoshimura, H., Kanno, A., and Ozawa, T. (2013) Bioluminescent probes to analyze ligand-induced phosphatidylinositol 3,4,5- trisphosphate production with split luciferase complementation. Anal. Chem. 85, 11352–11359.

(63) Miles, R. R., Perry, W., Haas, J. V, Mosior, M. K., Cho, M. N., Wang, J. W. J., Yu, P., Calley, J., Yue, Y., Carter, Q., Han, B., Foxworthy, P., Kowala, M. C., Ryan, T. P., Solenberg, P. J., and Michael, L. F. (2013) Genome-wide screen for modulation of hepatic apolipoprotien A-I(ApoA-I) secretion. J. Biol. Chem. 288, 6386–6396.

(64) Siles, S. A., Srinivasan, A., Pierce, C. G., Lopez-Ribot, J. L., and Ramasubramanian, A. K. (2013) High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob. Agents Chemother. 57, 3681–3687.

(65) Waller, C. F. (2014) Imatinib mesylate. Recent Results Cancer Res. 201, 1–25.

(66) Hantschel, O., Rix, U., and Superti-Furga, G. (2008) Target spectrum of the BCRABL inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma 49, 615–619.

(67) Moryoussef, F., Dhooge, M., Volet, J., Barbe, C., Brezault, C., Hoeffel, C., Coriat, R., and Bouché, O. (2015) Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib. J. Cachexia. Sarcopenia Muscle 6, 343–350.

(68) Parmar, S., Katsoulidis, E., Verma, A., Li, Y., Sassano, A., Lal, L., Majchrzak, B., Ravandi, F., Tallman, M. S., Fish, E. N., and Platanias, L. C. (2004) Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate ( STI571 ) in BCR-ABL-expressing Cells. J. Biol. Chem. 279, 25345–25352.

(69) Perdiguero, E., Ruiz-Bonilla, V., Gresh, L., Hui, L., Ballestar, E., Sousa-victor, P., Baeza-raja, B., Esteller, M., Serrano, A. L., and Erwin, F. (2007) Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38α in abrogating myoblast proliferation. EMBO J. 26, 1245–1256.

(70) Wu, Z., Woodring, P. J., Bhakta, K. S., Tamura, K., Wen, F., Feramisco, J. R., Karin, M., Wang, J. Y. J., and Puri, P. L. (2000) p38 and Extracellular SignalRegulated Kinases Regulate the Myogenic Program at Multiple Steps. Mol. Cell. Biol. 20, 3951–3964.

(71) Omo, G. D., Penno, G., Prato, S. Del, Pedrinelli, R., Omo, D., and Prato, D. (2007) Doxazosin in metabolically complicated hypertension. Expert Rev Cardiovasc Ther. 5, 1027–1035.

(72) Boesch, S. T., Corvin, S., Zhang, J., Rogatsch, H., Bartsch, G., and Klocker, H. (1999) Modulation of the Differentiation Status of Cultured Prostatic Smooth Muscle Cells by an α1-Adrenergic Receptor Antagonist. Prostate 39, 226–233.

(73) Ogle, B. M., Cascalho, M., and Platt ||, J. L. (2005) Biological implications of cell fusion. Nat. Rev. | Mol. CELL Biol. 6, 567–575.

(74) Hernadez, J. M., and Podbilewicz, B. (2017) The hallmarks of cell-cell fusion. Development 144, 4481–4495.

(75) Bastida-Ruiz, D., Hoesen, K. Van, and Cohen, M. (2016) The dark side of cell fusion. Int. J. Mol. Sci. 17, 638.

参考文献をもっと見る